知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

24 records (took 0.023 seconds)

    BIOMARKER FOR HYPERTENSIVE DISORDERS OF PREGNANCY
    1.
    发明申请
    BIOMARKER FOR HYPERTENSIVE DISORDERS OF PREGNANCY 审中-公开
    PROMNANCY的高血压病人的生物标记

    公开(公告)号：US20130116151A1

    公开(公告)日：2013-05-09

    申请号：US13809123

    申请日：2011-07-08

    Applicant: Koen Kas

    Inventor： Koen Kas

    IPC: G01N33/68

    CPC classification number: G01N33/689 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N2333/90212 ,  G01N2500/04 ,  G01N2800/368 ,  G01N2800/50 ,  G01N2800/56

    Abstract: The application discloses a new tool for predicting, diagnosing and prognosing hypertensive disorders of pregnancy and particularly preeclampsia; methods for the diagnosis, prediction, prognosis and/or monitoring said disorders; and kits and devices for measuring said biomarker and/or performing said methods.

    Abstract translation: 该应用公开了一种预测，诊断和预测妊娠高血压疾病，特别是先兆子痫的新工具; 用于诊断，预测，预后和/或监测所述疾病的方法; 以及用于测量所述生物标志物和/或执行所述方法的试剂盒和装置。

    USE OF APTAMERS IN PROTEOMICS
    5.
    发明申请
    USE OF APTAMERS IN PROTEOMICS 审中-公开
    APTAMERS在PROTEOMICS中的应用

    公开(公告)号：US20100298152A1

    公开(公告)日：2010-11-25

    申请号：US12682537

    申请日：2008-10-10

    Applicant: Clive Gavin Brown ,  Koen Kas ,  Sven Agnes Jan Eyckerman

    Inventor： Clive Gavin Brown ,  Koen Kas ,  Sven Agnes Jan Eyckerman

    IPC: C40B20/04 ,  C40B20/00 ,  C07K14/00 ,  C07H21/02 ,  C07H21/04

    CPC classification number: C12Q1/6804 ,  C12N15/111 ,  C12N15/115 ,  C12N2310/16 ,  C12N2320/11 ,  G01N33/6818

    Abstract: The present invention is a method for measuring the amount of at least one molecule in a biological sample, the method comprising a) combining the sample, or a derivative thereof, with one or more aptamers and allowing one or more molecules in the sample to bind to the aptamer(s); b) separating bound from unbound molecules; and c) quantifying the molecule(s) bound to the or each aptamer, wherein quantification of the bound molecule(s) is carried out by sequencing at least part of the or each aptamer. Uses of and products derived from the method are also contemplated.

    Abstract translation: 本发明是用于测量生物样品中至少一种分子的量的方法，该方法包括：a）将样品或其衍生物与一种或多种适体组合并使样品中的一种或多种分子结合 适应症; b）从未结合的分子分离结合物; 和c）定量与所述或每个适体结合的分子，其中结合分子的定量是通过测序至少一部分或每个适体进行的。 还考虑了使用和衍生自该方法的产品。

    BIOMARKERS AND METHODS FOR DIAGNOSING, PREDICTING AND/OR PROGNOSING SEPSIS AND USES THEREOF
    6.
    发明申请
    BIOMARKERS AND METHODS FOR DIAGNOSING, PREDICTING AND/OR PROGNOSING SEPSIS AND USES THEREOF 审中-公开
    用于诊断，预测和/或预防接触的生物标记物和方法及其用途

    公开(公告)号：US20100292131A1

    公开(公告)日：2010-11-18

    申请号：US12742647

    申请日：2008-11-12

    Applicant: Koen Kas ,  Griet Vanpoucke ,  Sven Degroeve ,  Kathleen Huijben

    Inventor： Koen Kas ,  Griet Vanpoucke ,  Sven Degroeve ,  Kathleen Huijben

    IPC: A61K38/00 ,  C40B30/04 ,  C40B40/10 ,  C40B50/02 ,  G01N33/53 ,  A61P5/00

    CPC classification number: G01N33/6893 ,  C07K17/02 ,  G01N2800/26 ,  G01N2800/50 ,  G01N2800/52

    Abstract: The present invention provides kits and methods for the diagnosis, prognosis and prediction of sepsis in a subject or for the differentiation between sepsis and SIRS in a subject, the method comprising(a) measuring the level of pro-hepcidin (pro-HEPC) in a biological sample taken from said subject, (b) measuring the level of at least one further biomarker selected from the group consisting of soluble TNF-receptor 2 (sTNFR2), Pentraxin-3 (PTX-3), Macrophage Colony-Stimulating Factor (MCSF), pro-Brain Natriuretic Protein (pro-BNP), one or more members of the Histone protein family, Procalcitonin (PCT) and c-Reactive Protein (CRP) in a biological sample from said subject, (c) using said measurements obtained in steps (a) and (b) to create a profile for said biomarkers and (d) comparing said profile with a reference biomarker profile obtained form a patient having SIRS or from a healthy subject.

    Abstract translation: 本发明提供了用于诊断，预后和预测受试者中败血症或受试者中脓毒症和SIRS之间的分化的试剂盒和方法，所述方法包括（a）测量前体铁调素（pro-hepcidin） 从所述对象获取的生物样品，（b）测量至少一种选自下组的生物标志物的水平：可溶性TNF-受体2（sTNFR2），Pentraxin-3（PTX-3），巨噬细胞集落刺激因子 MCSF），前脑利钠蛋白（pro-BNP），组蛋白家族中的一个或多个成员，来自所述受试者的生物样品中的降钙素原（PCT）和C-反应蛋白（CRP），（c）使用所述测量 在步骤（a）和（b）中获得以产生用于所述生物标志物的分布图，（d）将所述分布与从具有SIRS或健康受试者的患者获得的参考生物标志物概况进行比较。

    TRANSACTION METHOD BASED ON THE GENETIC IDENTITY OF AN INDIVIDUAL AND TOOLS RELATED THEREOF
    9.
    发明申请
    TRANSACTION METHOD BASED ON THE GENETIC IDENTITY OF AN INDIVIDUAL AND TOOLS RELATED THEREOF 审中-公开
    基于与其相关的个人和工具的遗传识别的交易方法

    公开(公告)号：US20140236833A1

    公开(公告)日：2014-08-21

    申请号：US14349479

    申请日：2012-10-05

    Applicant: Koen KAS

    Inventor： Koen Kas

    IPC: G06Q20/40 ,  G06Q20/08 ,  G06Q20/32 ,  G06F19/24

    CPC classification number: G06Q20/40145 ,  G06Q20/0855 ,  G06Q20/3224 ,  G06Q30/0601 ,  G16B40/00 ,  G16B50/00

    Abstract: The current invention relates to a method for establishing a transaction between an individual and a third party, based on the genetic identity of an individual, characterized in that said individual allows third party to access and analyze only a subset of said genetic identity, required for the offer and establishment of the transaction. In a second aspect, the invention discloses tools for the analysis of the genetic identity of individuals.

    Abstract translation: 本发明涉及一种基于个体的遗传特性来建立个人与第三方之间的交易的方法，其特征在于，所述个体允许第三方仅访问和分析所述遗传身份的子集， 交易的提议和建立。 在第二方面，本发明公开了用于分析个体遗传特性的工具。

    Biomarker for diagnosis, prediction and/or prognosis of sepsis and uses thereof
    10.
    发明授权
    Biomarker for diagnosis, prediction and/or prognosis of sepsis and uses thereof 失效
    用于诊断，预测和/或脓毒症预后的生物标志物及其用途

    公开(公告)号：US08697370B2

    公开(公告)日：2014-04-15

    申请号：US12990841

    申请日：2009-05-19

    Applicant: Koen Kas ,  Griet Vanpoucke

    Inventor： Koen Kas ,  Griet Vanpoucke

    IPC: G01N31/00 ,  G01N33/53

    CPC classification number: G01N33/6893 ,  G01N2800/26 ,  G01N2800/56

    Abstract: Methods for the diagnosis, prognosis and prediction of sepsis in a subject using the expression levels of the biomarkers Triggering Receptor Expressed on Myeloid cells-1 (TREM-1) and TREM-like receptor transcript-1 (TLT1) as an indication of the condition of the patient, alone or in combination with further sepsis markers are disclosed. If the levels of the biomarkers indicate the presence of sepsis, the patient is treated for sepsis with an antibiotic and/or fluid resuscitation treatment.

    Abstract translation: 使用骨髓细胞-1（TREM-1）和TREM样受体转录物-1（TLT1）表达的生物标志物触发受体的表达水平来诊断，预后和预测败血症的方法作为病症的指征 的患者，单独或与进一步的败血症标记物组合。 如果生物标志物的水平表明存在败血症，则用抗生素和/或液体复苏治疗对患者进行败血症治疗。

Patent Agency Ranking